Fewer Gastrointestinal Bleeds With Ticagrelor and Prasugrel Compared With Clopidogrel in Patients With Acute Coronary Syndrome Following Percutaneous Coronary Intervention

Neena S. Abraham; Eric H. Yang; Peter A. Noseworthy; Jonathan Inselman; Xiaoxi Yao; Jeph Herrin; Lindsey R. Sangaralingham; Che Ngufor; Nilay D. Shah


Aliment Pharmacol Ther. 2020;52(4):646-654. 

In This Article


We clarify the comparative GIB risk associated with three P2Y12 inhibitors in a national cohort of ACS patients following coronary reperfusion therapy in routine practice. Prescription of ticagrelor is associated with up to a 37% reduction of GIB within the first year following index prescription when compared to clopidogrel in all patients undergoing PCI for ACS. Prasugrel is associated with a 36% reduction in GIB among STEMI patients.